Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

Colaboración

Año: 2023

Morales-Cano, D; Izquierdo-García, JL; Barreira, B; Esquivel-Ruiz, S; Callejo, M; Pandolfi, R; Villa-Valverde, P; Rodríguez, I; Cogolludo, A; Ruiz-Cabello, J; Perez-Vizcaino, F; Moreno, L

Título: FRONTIERS IN PHARMACOLOGY

• Q1